Immunitybio Inc Revenue Growth Rates (IBRX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Immunitybio inc   (NASDAQ: IBRX)
 

IBRX's Revenue Growth by Quarter and Year

Immunitybio Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/IBRX/growth
https://api.csimarket.com/api/v1/companies/IBRX/fundamentals
https://api.csimarket.com/api/v1/companies/IBRX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
IBRX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 48.84
2nd Quarter June 51.24
1st Quarter March 44.21
FY 144.29

IBRXs Annual Revenue
Immunitybio Inc 's Revenue in the fiscal year 2025 $ 113.29 millions
Immunitybio Inc 's Revenue in the fiscal year 2024 $ 14.75 millions
Immunitybio Inc 's Revenue in the fiscal year 2023 $ 0.62 millions
Immunitybio Inc 's Revenue in the fiscal year 2022 $ 0.24 millions
Immunitybio Inc 's Revenue in the fiscal year 2021 $ 0.93 millions




IBRX Revenue third quarter 2026 Y/Y Growth Comment
Immunitybio inc reported Revenue rise of 52.34% year on year in the third quarter 2026, to $ 48.84 millions, this is lower than Immunitybio Inc 's recent average Revenue surge of 2154.28%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Revenue growth. While Immunitybio Inc ' s Revenue jump of 52.34% ranks overall at the positon no. 289 in the third quarter 2026.


IBRX Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 52.34 %
2nd Quarter June 93.87 %
1st Quarter March 167.62 %
FY   -

Financial Statements
Immunitybio Inc 's third quarter 2026 Revenue $ 48.84 millions IBRX's Income Statement
Immunitybio Inc 's third quarter 2025 Revenue $ 32.06 millions Quarterly IBRX's Income Statement


IBRX Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -4.68 %
2nd Quarter June 15.9 %
1st Quarter March 15.46 %
FY (Year on Year)   -


Back to IBRX Growth rate Comparisons >> Back to IBRX Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #15
Healthcare Sector #77
Overall #289

Revenue Y/Y Growth Statistics
High Average Low
41192.5 % 2154.28 % -95 %
(Mar 31 2025)   (Dec 31 2022)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #15
Healthcare Sector #77
Overall #289
Revenue Y/Y Growth Statistics
High Average Low
41192.5 % 2154.28 % -95 %
(Mar 31 2025)   (Dec 31 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Immunitybio Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
6700 % 251.94 % -96.41 %
(Sep 30 2020)  


IBRX's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Immunitybio Inc disclosed fall in Revenue from the second quarter by -4.68% to $ 48.84 millions, from $ 51.24 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 15 other companies have achieved higher Revenue quarter on quarter growth. While Immunitybio Inc 's Revenue growth quarter on quarter, overall rank is 621.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #16
Healthcare Sector #113
Overall #621
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #16
Healthcare Sector #113
Overall #621
Revenue Q/Q Growth Statistics
High Average Low
6700 % 251.94 % -96.41 %
(Sep 30 2020)  


IBRX's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Immunitybio Inc disclosed fall in Revenue from the second quarter by -4.68% to $ 48.84 millions, from $ 51.24 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 15 other companies have achieved higher Revenue quarter on quarter growth. While Immunitybio Inc 's Revenue growth quarter on quarter, overall rank is 621.


Immunitybio Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 165.79
Y / Y Revenue Growth (TTM) 192.92 %
Year on Year Revenue Growth Overall Ranking # 10
Seqeuential Revenue Change (TTM) 17.6 %
Seq. Revenue Growth (TTM) Overall Ranking # 197


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Immunitybio Inc 's cumulative twelve months Revenue were $ 166 millions, company would post below average annual Revenue growth of 17.6% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Immunitybio Inc 's Revenue growth from the 51.24% growth in Mar 31 2026.

Among companies within the Healthcare sector 4 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 6 to 10.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 9
Healthcare Sector # 5
Overall # 10

Revenue TTM Y/Y Growth Statistics
High Average Low
10238.41 %
 539.93 %
-90.27 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 55
S&P 500 # 197
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Immunitybio Inc 's cumulative twelve months Revenue were $ 166 millions, company would post below average annual Revenue growth of -90.27% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Immunitybio Inc 's Revenue growth from the 51.24% growth in Mar 31 2026.

Among companies within the Healthcare sector 4 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 6 to 10.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 9
Healthcare Sector # 5
Overall # 10

Revenue TTM Y/Y Growth Statistics
High Average Low
10238.41 %
539.93 %
-90.27 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 55
S&P 500 # 197




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IBRX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Nuo Therapeutics Inc 80.81%$ 80.809 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Therapeuticsmd Inc 60.59%$ 60.587 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions


About Immunitybio Inc Revenue Growth Rates (IBRX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Immunitybio Inc (CIK 1326110).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001326110-26-000099
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Immunitybio Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.